# CLPT — ClearPoint Neuro, Inc.

## Company & Research Metadata

- **Company:** ClearPoint Neuro, Inc.
- **Ticker:** CLPT
- **Exchange:** Nasdaq
- **Sector / Industry:** Health Care / neurosurgical and drug-delivery technology
- **Template version:** 2.7
- **Research date:** 2026-11-07
- **Valuation refresh date:** 2026-11-07
- **Valuation / score price snapshot:** $8.60 — 2026-11-06 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Primary operating period reviewed:** Q3 2026
- **Historical period reviewed:** FY 2024, FY 2025; Q1, Q2, Q3 and 9M 2026 (quarterly/YTD FCF and SBC)
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q3 2026, complete material Q&A (October 28)
- **Latest post-earnings management commentary reviewed:** November 2, 2026 uniQure FDA acceptance and Priority Review; issuer's November 4 update

- **Price snapshot date:** 2026-11-06

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-11-07

**Previous Review:** 2026-10-28 (fundamental valuation originating 2026-10-21)

**Update Trigger:** Q3 2026 earnings, lower guidance, cash and dilution, uniQure FDA review milestone, updated valuation

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Revenue and mix | Q2 2026 revenue $10.9M; biologics declined 15% | Q3 revenue $12.075M (+36% YoY); biologics $4.9M (+11%); neurosurgery $5.4M (+59%, partly acquired IRRAflow); equipment $1.7M (+68%) | Better commercial momentum, but headline growth includes acquired business |
| Profit and cash | 62% Q2 gross margin; $29.4M cash at June end | Q3 gross margin 58.5%, operating loss $6.332M; $46.184M cash at September end after $22.020M ATM proceeds | Sequential expense leverage improved; gross economics and external funding remain issues |
| Outlook | 2026 revenue guidance $48–52M | Reduced to $48–50M, versus $52–56M in May; mid-teens underlying 2027 growth is preliminary, not formal guidance | Lower near-term forecast challenges the former $105M 2029 base revenue case |
| Partner regulatory catalyst | uniQure BLA submitted | AMT-130 accepted for Priority Review on November 2; FDA target May 1, 2027; ClearPoint companion 510(k) is still required | Raises confidence that regulatory review is progressing, not that commercialization is assured |
| Valuation | Bear/base/bull $1.29/$7.93/$24.01, weights 35/45/20, P/W $8.82 | Bear/base/bull $1.19/$6.55/$21.38, same weights, P/W $7.64 | -13.4% fundamental value revision from revenue, dilution and debt/cash burden; current price movement is separate |
| Quality and confidence | Quality 54.3 / Speculative; confidence 24/100 | Retained after explicit reassessment | Stronger pipeline progress offset by weaker guidance, cash demands and dilution |

**Thesis:** Mixed; the clinical platform is advancing, but the per-share economics are weaker than previously modeled. The lower price does not by itself change fundamental value. Historic price-based rankings remain historical; FolioFacts calculates live zones, return and rank.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $8.60 — November 6, 2026 close (dated valuation reference, not live) |
| Bear / Base / Bull Fair Value | $1.19 / $6.55 / $21.38 |
| Scenario Probabilities | 35% / 45% / 20% |
| Probability-Weighted Fair Value | $7.64 |
| Fundamental rating at dated reference price | Avoid — approximately 11.1% below $8.60 on probability-weighted value; speculative / very-high-risk business |
| Quality Score / Tier | 54.3 / Speculative |
| Valuation Confidence | 24 / 100 |
| Risk Level | Very High |
| Tracking / Ownership | Primary Watchlist / Not Owned |

**Decision rationale:** ClearPoint's therapy-delivery positioning and emerging products could compound through higher recurring procedural sales. Yet the stock at the November 6 research price lacks adequate margin of safety given an $8.82-to-$7.64 decrease in weighted fair value, reduced 2026 guidance, 2027 debt cash demands, and dilution. This is a dated fundamental assessment, not FolioFacts' live price zone or Opportunity Score.

## Investment Thesis

ClearPoint sells specialized equipment, reusable hardware, disposable instruments, clinical support, and preclinical services that allow neurosurgeons and biopharma sponsors to navigate and deliver therapies to precise brain and spinal targets. The strongest economic outcome would be a growing installed base of treatment centers using ClearPoint disposables repeatedly as new medicines reach patients. A device-platform investment can benefit from many partner programs without financing every drug trial itself, but trial delays and correlated regulatory failure remain real.

Q3 shows that underlying clinical products and laboratory services can grow. The 36% consolidated increase partly reflects IRRAflow acquired in late 2025, while gross margin fell and annual guidance was reduced. The company also issued 1.53M shares during the quarter. The thesis therefore depends on incremental gross profit per procedure growing faster than capital demands and dilution.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Gene-therapy approvals | uniQure's AMT-130 Priority Review is a milestone, not a forecast of guaranteed ClearPoint commercial revenue; device-specific approval/review also matters |
| Procedure reuse | New navigation, IRRAflow, Prism and drug-delivery placements may create recurring disposable revenue, but utilization and margin per procedure must be reported and demonstrated |
| Financing | $46.2M of cash was replenished by an ATM issuance, while operating cash use remains high and Oberland revenue-sharing begins in 2027 |

## Business Overview

ClearPoint's business combines three disclosed revenue groupings. **Neurosurgery navigation and therapy** sells disposables used with its ClearPoint system, Prism laser, and acquired IRRAflow portfolio. **Biologics and drug delivery** sells products and paid services to therapy developers through preclinical and clinical work, including ClearPoint Advanced Laboratories (CAL). **Capital equipment and software** supplies the navigation systems, IRRAflow controls, and laser systems that help establish future use at centers.

Hospitals, neurosurgeons, research centers, and biopharma partners purchase these products through sales and clinical support teams. Equipment revenue is periodic, while case consumables and lab contracts can recur, though trial timing is uneven. IRRAflow acquired in November 2025 expanded offerings but makes year-over-year comparison less purely organic.

| Revenue stream | Q3 2025 | Q3 2026 | Growth | Economic read-through |
|---|---:|---:|---:|---|
| Neurosurgery navigation & therapy | ~$3.4M | ~$5.4M | +59% | IRRAflow acquisition plus legacy product growth |
| Biologics & drug delivery | ~$4.4M | ~$4.9M | +11% | Predominantly more CAL services this quarter |
| Capital equipment & software | ~$1.0M | ~$1.7M | +68% | Installations may feed disposable usage |

### Business Takeaway

The installed systems and therapies can become a repeat-procedure business if hospital utilization and treatment approvals increase. Counting equipment placements or partner programs without tracking profitable procedure use would overstate current earnings power.

## Industry, TAM & Market Share

Neurodegenerative diseases, movement disorders, brain tumors, and CNS gene therapy are large clinical needs, but a company-specific, directly comparable addressable market cannot be measured reliably from broad patient counts. Actual device opportunities depend on trial enrollment, approvals, physician training, reimbursement, treatment-center rollout, and treatment competition. uniQure's AMT-130 reached FDA Priority Review with a May 1, 2027 action target; acceptance for review does not equal approval.

### Market-Share Analysis

Publicly disclosed product-specific procedure and installed-base metrics for ClearPoint, Medtronic and private competitors use different definitions. No reliable comparable market-share percentage series was established.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Monteris Medical (private) | Direct segment: NeuroBlate MRI-guided laser ablation | Specialist product; no matched share data | Competes in cranial laser procedures | Direct product substitute in one procedure category |
| Medtronic (MDT) | Direct segments: Visualase laser and StealthStation navigation | Broader installed footprint | Mature competing neurosurgical workflows | Scale and distribution challenge |
| Zimmer Biomet — ROSA Brain | Substitute stereotactic robotic navigation | Different workflow; no matched share data | Alternate guidance approach | Can displace selected navigation workflows |

### Industry Takeaway

Clinical demand is real, but ClearPoint's revenue opportunity is its share of commercially delivered, reimbursed procedures—not the gross population of all patients with neurological conditions.

## Customer Economics

The most attractive model is repeated utilization of installed hardware with disposable tools, software, and case support. Q3 equipment placements broaden the potential base; management expects Q3 installations to contribute to Q4 and later consumables. The company has not disclosed a comparable complete center-utilization series, per-procedure gross profit, or a reconciled net revenue retention metric.

Laboratory services can deepen partner relationships but require pre-revenue facility investment. Management expects new histology capability to require equipment and hiring three to six months before monetization. Regulatory approvals can change volume substantially, but there is no disclosed conversion schedule reliable enough to treat partner pipelines as booked revenue.

### Customer-Economics Takeaway

Growing procedure frequency, retention at treatment centers, and contribution margin after field clinical support are more decisive than the number of facilities or drug-development partners.

## Competitive Landscape & Moat

### Competitive Landscape

Neurosurgical navigation, laser ablation and biologics delivery require separate comparisons. PROCEPT’s prostate-surgery systems do not compete for these procedures.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Monteris Medical (private) | No consistent comparable series | Direct segment: NeuroBlate MRI-guided laser ablation | Dedicated neuro-ablation platform | Not equivalent to ClearPoint's full biologics-delivery offering | Competes in laser-ablation procedures |
| Medtronic (MDT) | No consistent comparable series | Direct segments: Visualase ablation and StealthStation navigation | Hospital navigation installed base | Conventional navigation differs from real-time MRI-guided delivery | Competes in selected neurosurgical workflows |
| Zimmer Biomet — ROSA Brain | No consistent comparable series | Substitute: robotic stereotactic neurological guidance | Operating-room robotic workflow | Different imaging/workflow from MRI-guided ClearPoint | Alternative guidance approach, not identical technology |

### Moat Assessment

Specialized navigation, physician familiarity and partner integration create useful know-how and switching costs. The moat is narrower than that of an established large device platform, with financial resources and commercialization reach remaining constraints.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Specialized navigation, physician familiarity and partner integration create useful know-how and switching costs. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2024 | 31.39 | 31.04% | 60.92% | -62.87% | -9.23 | -29.39% | 6.91 | 27 | 20.10 | 3.57 |
| FY2025 | 36.97 | 17.78% | 61.38% | -60.49% | -24.45 | -66.13% | 8.18 | 28 | 45.92 | 58.23 |
| Q1 FY2026 | $12.128 | N/D | 64.0% | -69.9% | −$8.612 (derived: CFO - capex) | -71.0% | $2.218 | 29.547 | $35.593 | N/D |
| Q2 FY2026 | $10.88 | N/D | 61.7% | -94.2% | −$7.229 (derived: current YTD - prior YTD) | -66.4% | $2.271 (derived: current YTD - prior YTD) | 30.167 | $29.363 | N/D |
| H1 FY2026 | $23.008 | N/D | 62.9% | -81.4% | −$15.841 (derived: CFO - capex) | -68.8% | $4.489 | 29.858 | $29.363 | N/D |
| Q3 FY2026 | $12.075 | N/D | 58.5% | -52.4% | −$20.237 (derived: current YTD - prior YTD) | -167.6% | $1.88 (derived: current YTD - prior YTD) | 30.983 | $46.184 | N/D |
| 9M FY2026 | $35.083 | N/D | 61.4% | -71.4% | −$21.09 (derived: CFO - capex) | -60.1% | $6.369 | 30.238 | $46.184 | N/D |

### Financial Takeaways

Q3 revenue grew 36.3% year over year but includes IRRAflow acquired in November 2025. Gross margin of 58.46% fell from 63.2% last year, largely from CAL overhead and acquisition amortization. Operating expenses were $13.391M versus $10.876M last year, but eased sequentially from approximately $16.9M in Q2; operating loss was $6.332M. Net loss was $7.460M, compared with $5.891M in Q3 2025.

Nine-month operating cash used rose to $20.094M from $11.845M. Capex was $0.996M, versus $0.473M, producing nine-month FCF of -$21.090M. Q3 estimated cash use including capex improved sequentially to -$5.249M. SBC was $1.880M in Q3 and $6.369M for nine months; compare SBC with matched periods, not trailing fabricated totals. With negative FCF, SBC as a percentage of FCF is economically misleading rather than a healthy payout measure.

Cash rose to $46.184M only after $22.020M net ATM proceeds in Q3. The company issued 1.53M ATM shares that quarter, and common shares outstanding increased from 29.369M at year-end 2025 to 32.051M on September 30 (+9.1%). Notes payable, net, were $50.840M; lease liabilities are additional obligations, not double-counted as conventional funded debt.

Oberland notes bear 8.25–9.50% cash/PIK contractual interest terms, with an effective interest rate of 11.3% at September end. Cash interest increases when PIK periods end. Starting Q1 2027, the lender receives 0.525% of defined net revenue (including the added tranche percentage), subject to terms in the financing contract. This is a claim on future cash generation.

**Financial direction:** Mixed — sequential operating cash burn improved, while consolidated gross margins, cumulative losses and dilution remain serious constraints.

## Management & Capital Allocation

Management reduced 2026 revenue guidance from $52–56M in May to $48–52M in August and then $48–50M in October. The midpoint declined by $5M from the May projection. There was improved Q3 operating leverage, including commercial reorganization and IRRAflow integration savings, but management's ability to deliver the implied Q4 step-up remains an immediate credibility test.

The company used its ATM offering to raise $22.020M net in Q3, primarily to fund CAL setup, commercial/clinical support and technology development. The focused ultrasound, robotics, spine-laser and IRRAflow portfolios may generate attractive long-run opportunities but require up-front spending. Management expects gradually declining operating burn over four to six quarters, with separate CAL capex needs; those are expectations, not guidance to profitability. The preliminary mid-teens 2027 underlying growth comment is not formal FY2027 guidance.

### Management Takeaway

Reinvestment is rational only if the new offerings generate enough case revenue, gross profit and durable cash flow to outweigh financing costs and additional shares.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $8.60 — November 6, 2026 regular-session close |
| Shares outstanding | 32.051M — September 30, 2026 |
| Market capitalization | ~$275.64M (dated price × reported shares) |
| Cash | $46.184M — September 30, 2026 |
| Funded notes payable, net | $50.840M — September 30, 2026 |
| Net debt (notes less cash) | ~$4.66M; excludes operating leases and accrued interest |
| Enterprise Value | ~$280.30M (simple notes/cash basis) |
| 2026 guided sales midpoint | $49.0M |
| EV / FY2026 guided sales | ~5.72× |
| Trailing / forward P/E | N/A: loss-making |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| CLPT — ClearPoint Neuro | Subject | Public | N/A (net loss) | ~5.72× FY2026E, dated 2026-11-06 | 36.3% reported Q3 growth, part acquired; -52.4% Q3 operating margin |
| Monteris Medical | Competing NeuroBlate laser procedure | Private | N/A | N/A | Private specialized direct competitor |
| MDT — Medtronic | Selected Visualase/StealthStation direct products; diversified parent | Public | 15.76 (historic 2026-10-20) | 3.60 (historic 2026-10-20) | Parent-wide rather than competing-product economics |
| Zimmer Biomet — ROSA Brain | Alternate stereotactic workflow | Public parent/product unit | N/D | N/D | Different procedure workflow; no matched segment multiple |

**Comparable takeaway:** The premium to diversified Medtronic cannot be converted directly into a target multiple: ClearPoint is smaller, faster-growing and loss-making, with much greater financing risk.

### Valuation Scenarios

Dated research model: projected late-2029 enterprise sales value, minus scenario forecast net debt, divided by scenario diluted shares and discounted back three years at 18%. These are independent investment assumptions, not official company guidance.

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 2029 sales $60M; 2× EV/sales; 41M diluted shares; $40M forecast net debt; 18% discount. Partner delays and continued cash use suppress revenue and per-share value. | $1.19 | 35% | Commercialization and funding outcomes remain uncertain | -86.2% |
| Base | 2029 sales $90M; 5× EV/sales; 39M diluted shares; $30M forecast net debt; 18% discount. Gradual scale-up from installed equipment, procedures and CAL services. | $6.55 | 45% | Most likely scenario given preliminary mid-teens 2027 underlying growth and later therapy options | -23.8% |
| Bull | 2029 sales $165M; 8× EV/sales; 37M diluted shares; $20M forecast net debt; 18% discount. Several therapies commercialize and margins improve. | $21.38 | 20% | Upside requires substantial successful program conversion and high utilization | +148.6% |
| **Probability-Weighted** | Probability sum of modeled fair values; unchanged probabilities 35/45/20 | **$7.64** | **100%** | Judgmental probability mix | **-11.1%** |

### Valuation Takeaway

- **Primary valuation method:** Discounted late-2029 sales-multiple scenarios, less forecast net debt and divided by scenario diluted shares; 18% annual discount over three years. Independent research assumptions, not official guidance.
- **Cross-check methods:** Dated current EV/FY2026 guided sales (~5.72×), historic Medtronic group multiple (not a direct product valuation), operating cash conversion and forecast share dilution.
- **Key valuation dependencies:** Regulatory approval and paid procedures for AMT-130 and other partners; follow-on disposable utilization at newly installed sites; gross margins; cash interest, revenue-participation costs and possible additional equity.
- **Previous approved (October 2026) values:** bear/base/bull $1.29/$7.93/$24.01, weighted $8.82; 2029 sales $60M/$105M/$180M; 40M/38M/36M scenario shares, $35M/$30M/$20M net debt. The 18% discount rate and 35/45/20 probabilities were retained after explicit reassessment.
- **Revised:** Bear revenue and multiple retained at $60M and 2×; net debt/share count increased. Base 2029 sales lowered $105M → $90M, diluted shares 38M → 39M. Bull sales lowered $180M → $165M, diluted shares 36M → 37M. These revisions reflect lowered guidance, prospective debt cash obligations and ATM dilution. The uniQure regulatory milestone improves optionality but is not approval or guaranteed sales.
- **Fair-value change:** $8.82 → $7.64 (-13.4%) from fundamental assumptions, distinct from the reference share-price change.
- **Valuation confidence / Risk Level:** 24/100 / Very High retained: the near-term regulatory event is now firmer but long-run volumes, economics and future equity funding still dominate. Quality 54.3 / Speculative retained since improved commercial momentum is offset by weaker guidance and financial sustainability.
- **Margin-of-safety conclusion:** Avoid at $8.60, based on fundamental weighted return of -11.1%; FolioFacts owns live zones/ranks and may differ after a price move. The standard theoretical zone thresholds from $7.64 weighted value and $1.19 bear value are: Strong Buy ≤$1.31; Buy through $6.11; Hold/Watch through $8.49; Avoid above $8.49. These are reference bounds, not a live feed.

## Analyst Questions

The following are independent paraphrases of the **Q3 2026 (October 28) analyst Q&A**, not transcript quotations. The three participating firms' material exchanges and follow-ups are represented.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Frank Takkinen / Lake Street | Which partner milestones matter in first- versus second-half 2027, including commercialization and Phase III expansion? | Burnett identified uniQure's AMT-130 BLA and the prospective ClearPoint companion device filing, plus expansion of multiple Phase III trials from roughly 3–5 sites to as many as 15–20. Management deferred undisclosed partner-specific schedules to the partners. FDA BLA acceptance subsequently occurred Nov. 2, targeting a May 1, 2027 agency action. | Program progress increases prospective installed-base demand, not booked commercial treatment revenue. |
| Frank Takkinen / Lake Street | Are treatment centers and ClearPoint itself beginning to make the up-front investments anticipated for broader therapy delivery? | Management said hospital interest extends beyond individual surgeons to department and executive decision makers. ClearPoint is hiring and training clinical support staff and investing in robotics, focused ultrasound and capabilities that can generate CAL preclinical work ahead of device clearance; no aggregate committed customer investment figure was given. | New sites and staff create leverage only if sustained patient throughput follows. |
| Mathew Blackman / TD Cowen | How will operating cash burn and capex evolve over the next twelve months after the equity raise? | D'Alessandro expects additional CAL capex but improving operating leverage and gradual quarterly burn reductions over four to six quarters. Some early-2026 IRRAS costs were one-time. No binding numerical quarterly burn forecast was provided. | Cash runway forecasts should not treat sequential Q3 improvement as guaranteed. |
| Mathew Blackman / TD Cowen | What makes spine laser therapy technically different, and can the NCI-supported study support a future regulatory indication? | Burnett described spine-motion challenges for MRI heat measurements and potential utility of controlled breath-holds and ClearPoint's uncooled laser. Grant-supported evidence could help future clinical support, but the precise labeling/regulatory path remains undetermined. | It is a research and product-extension option, not approved new spine revenue. |
| Mathew Blackman / TD Cowen | What could ClearPoint earn per spine laser procedure? | Management suggested roughly $13K–$20K of possible revenue from laser, accessories and software, with about $15K as a planning midpoint, contingent on a future procedure business. | A unit-revenue concept is not procedure volume, margin or market size. |
| Tom Stephan / Stifel | What underlies the Q4 implied jump to the $49M full-year revenue midpoint and how predictable is it? | Burnett pointed to equipment delivery, disposable demand from installations and continuing CAL service expansion. Management warned that capital-equipment revenue is sensitive to whether installation closes before or after quarter-end; no guarantee of midpoint performance. | Q4 must deliver approximately $13.9M at midpoint, well above Q3's $12.075M. |
| Tom Stephan / Stifel | Is mid- to high-teens base business growth plausible in 2027, given the revised commercial organization and partner events? | Burnett offered a preliminary mid-teens underlying growth view, explicitly not FY2027 guidance, and expected early directional commentary around January. AMT-130, Phase III trials, CAL installation and IRRAflow regulatory programs could shift the outlook. | Supports lowering the earlier $105M base 2029 forecast to $90M absent demonstrated faster therapy conversion. |

### Analyst-Q&A Takeaway

The Q3 exchange emphasized practical near-term installation demand, cash discipline and the genuine uncertainty in procedure commercialization. The Nov. 2 FDA BLA acceptance resolves one regulatory review milestone but does not establish treatment approval or profitability.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| AMT-130 and partner Phase III therapies | uniQure BLA accepted for Priority Review, FDA action target May 1, 2027; companion ClearPoint 510(k) not yet authorized | Approval, device authorization and measurable recurring commercial procedures | Regulatory rejection/delay or restricted procedures | 2029 revenue distribution and scenario weights |
| Core clinical and equipment installation | Q3 neurosurgery $5.4M (+59%, acquired IRRAflow included), equipment $1.7M | Organic disposable growth and installed-system utilization reported consistently | Equipment placements fail to turn into repeated procedure sales | Sustainable revenue and exit multiple |
| CAL economics | Q3 biologics $4.9M (+11%); new facility adds overhead | Higher contribution margin and repeat services contracts as utilization scales | Costs exceed service revenue for extended period | Margin trajectory and cash burn |
| Liquidity and financing | $46.2M cash after $22.0M ATM financing; 9M FCF -$21.1M; Oberland revenue participation starts Q1 2027 | Operating burn declines without another large equity raise | Cash-interest burden and new shares absorb operating progress | Dilution, net-debt assumptions and per-share value |
| 2026–27 outlook | 2026 guidance lowered twice to $48–50M; 2027 mid-teens underlying view informal | Q4 revenue $12.917–14.917M and firm 2027 guidance with adequate visibility | Another miss or weaker-than-mid-teens base growth | Confidence and base-case 2029 sales |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 42 | 25% | 10.5 | Repeat procedure potential is attractive, but gross margin fell and sustainable contribution per case remains unproven. |
| Moat and competitive position | 65 | 25% | 16.3 | Specialized navigation, clinician workflow integration and partner relationships remain useful but narrowly scaled. |
| Growth runway and durability | 76 | 20% | 15.2 | AMT-130 Priority Review and Phase III expansion improve optionality; commercial conversion is not yet demonstrated. |
| Financial quality and balance sheet | 25 | 15% | 3.8 | $46.2M cash includes $22M issuance proceeds; nine-month FCF -$21.1M, gross-margin pressure and revenue-share debt obligations. |
| Management, governance and capital allocation | 57 | 15% | 8.5 | Integration savings and expanding clinical offerings offset guidance cuts and dilution. |
| **Quality Score** | **54.3** | **100%** | **54.3** | Weighted score, independent of ownership and current price |

- **Quality Tier:** Speculative
- **Speculative override:** Partner drug approvals, small scale and funding dependence create a commercialization override.

### Opportunity Score

FolioFacts owns live price-dependent opportunity calculations, current rankings and trading zones. The following **November 3, 2026 archived price-only snapshot** is preserved as history, not recalculated in this research update. Fundamental valuation and Quality Score above are updated on November 7.

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---:|---:|---:|
| Quality (historical) | 54.3 | 54.3 | 30% | 16.3 |
| Probability-weighted upside (Nov. 3 historic) | -9.2% | 31.7 | 35% | 11.1 |
| Bear-case downside (Nov. 3 historic) | -86.7% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence (historic) | 24 | 24.0 | 15% | 3.6 |
| **Historical Opportunity Score** |  |  | **100%** | **31.0** |

- **Historical rank:** #64 of 76, Nov. 3, 2026 price-only snapshot only.
- **Live opportunity, zone and rank:** Calculated by FolioFacts from the new $7.64 fundamental weighted fair value after research sync; do not overwrite these in stock_analysis.
- **Research-score conclusion:** Fundamental Quality 54.3 / Speculative and confidence 24/100 retained after Q3 reassessment; price-derived calculations deliberately not re-ranked in this repository.

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership and position size do not change fundamental research. FolioFacts—not this repository—computes price-sensitive Opportunity, rank and live zone.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $9.45 | Hold / Watch | Hold / Watch | >$1.42–$7.06 | ≤ $1.42 | > $9.80 | $7.93 | $8.82 | -6.7% | 54.3 | 32.7 / #53 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |
| 2026-11-07 research; Nov. 6 reference close | $8.60 | Avoid | Historical reference only; FolioFacts owns live zones | >$1.31–$6.11 | ≤$1.31 | >$8.49 | $6.55 | $7.64 | -11.1% | 54.3 | N/A — FolioFacts | Q3 re-underwriting: base 2029 sales $105M→$90M; more projected dilution and debt cash needs; uniQure review milestone recognized; prior history preserved |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [ClearPoint Neuro Q3 earnings release](https://ir.clearpointneuro.com/sec-filings/all-sec-filings/content/0001193125-26-436125/clpt-ex99_1.htm) | Company IR / filing | 2026-10-28 / Q3 | Revenue segments, gross margin, costs, guidance, strategic events |
| [Q3 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1285550/000119312526436412/clpt-20260930.htm) | Regulatory filing | 2026-09-30 | Nine-month cash flow, quarterly SBC, revenue, share count, net debt and Oberland terms |
| [Q3 2026 full earnings-call Q&A](https://stockanalysis.com/stocks/clpt/transcripts/722761-q3-2026/) | Transcript | 2026-10-28 | Management's Q4/2027 expectations, financing plans, clinical programs, analyst questions (paraphrased, not reproduced) |
| [Q2 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1285550/000119312526330842/clpt-20260630.htm) | Regulatory filing | 2026-06-30 | Quarter and six-month financial/SBC/FCF comparatives |
| [Q1 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1285550/000119312526221890/clpt-20260331.htm) | Regulatory filing | 2026-03-31 | First-quarter financial/SBC/FCF inputs |
| [ClearPoint Q1 earnings release](https://ir.clearpointneuro.com/news-events/press-releases/detail/1152/clearpoint-neuro-reports-first-quarter-2026-results) | Company IR | 2026-05-13 | Original $52–56M 2026 guidance and acquired-product contribution |
| [ClearPoint Q2 earnings release](https://ir.clearpointneuro.com/news-events/press-releases/detail/1156/clearpoint-neuro-reports-second-quarter-2026-results) | Company IR | 2026-08-03 | Prior $48–52M guidance and segment context |
| [uniQure Q3 update](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and) | Partner investor relations | 2026-11-04 | AMT-130 BLA accepted, Priority Review, target action date 2027-05-01 |
| [CLPT regular-session historical price](https://stockanalysis.com/stocks/clpt/history/) | Market research snapshot | 2026-11-06 | Dated research reference price only; not a redistribution feed |
| [ClearPoint 2025 10-K](https://www.sec.gov/Archives/edgar/data/1285550/000119312526111231/clpt-20251231.htm) | Regulatory filing | FY 2025 | Completed annual financials and relevant competing product context |
| [Medtronic valuation statistics](https://stockanalysis.com/stocks/mdt/statistics/) | Secondary public comparables | Historic 2026-10-20 | Previous peer snapshot, not a current subject-multiple input |
| [SEC XBRL company facts — CLPT](https://data.sec.gov/api/xbrl/companyfacts/CIK0001285550.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |